<DOC>
	<DOC>NCT02198443</DOC>
	<brief_summary>The main objective of this study is to compare the tolerability and adherence to a new drug regimen of post-exposure prophylaxis (PEP) for HIV,</brief_summary>
	<brief_title>Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Age greater than 18 years Have been exposed to HIV, nonoccupational and meets the requirements of current recommendations to start with three antiretroviral drugs PEP that adequately informed consent in writing to participate in the study and undergo testing and exploration that entails pregnant women, lactating, or those intend become pregnant during the study period. subjects who are known or suspected case presents the source resistors to one of the drugs of the pattern of study contraindicated treatment with the study drugs, or products under investigation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>